In a small, investigator-initiated phase 2 study by Dana-Farber Cancer Institute investigators, a novel combination of an antibody-drug conjugate and an immune checkpoint inhibitor showed notable activity in pre-treated patients with a difficult-to-treat form of endometrial cancer.
Age and underlying conditions increase risk of critical outcomes for hospitalized COVID-19 patients
Whether vaccinated or not, having at least four disease risk factors put adults hospitalized due to COVID-19 at higher risk for critical outcomes, according to
September 20, 2023